Skip to content
Open·Listed in the source's current feed today

Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

National Institutes of Health

Apply at National Institutes of Health

Want a reminder before this closes?

We'll email you 3 days before the deadline. One email, then we stop.

Free. Verify your email, then we send one reminder only.

Posted
Dec 17, 2025
Closes
Oct 25, 2027 (in 376 days)

See more open grant funding like this

Get alerted when new grant funding matching "cancer prevention control" opens, nationwide.

Checking your account…

Free includes 1 alert. New listings reach free search, alerts and AI search after 10 days. Unsubscribe anytime.

Classification and identifiers

Solicitation number
PAR-25-104
Assistance listing (CFDA)
93.399

Amount

Amount not listed here. Check the official program.

Who can apply

State governmentsNonprofitsPrivate universitiesSpecial districtsTribal governmentsSmall business

State government agencies, Nonprofits, including small and volunteer-run organizations, Private colleges and universities, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this opportunity

The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leadin...

Refine this search